Announcing the New Cancer Therapy Advisor Print Edition
We want to provide you with another useful, enduring resource that delivers relevant, up-to-date oncology information.
All articles by Nora Ray
Five Twitter Feeds Every Oncologist Should Follow
Twitter is a great way for oncology professionals to interact with their peers and patients, and CTA has recommendations for some feeds you should be following.
Different Name, Same Great Oncology Resource
Chemotherapy Advisor is changing its name to better reflect the changing landscape of cancer care.
Ibrutinib: Second FDA-Approved Drug with Breakthrough Therapy Designation for MCL
Ibrutinib has been given breakthrough therapy designation for treatment of mantle cell lymphoma.
Harnessing the Power of HIV to Kill Cancer
Although studies are still in their infancy, doctors are using T-cell immunotherapy to attack recurrent leukemic cancer cells, with astonishing results.
No Increased Cardiac Toxicity with Dual HER2 Blockade Therapy for Breast Cancer
Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.
PF-05280014, a Potential Biosimilar, Exhibits Similar PK Profile to Trastuzumab
PF-05280014, a potential biosimilar, was found to have an identical amino acid sequence and similar in vitro functional properties as the monoclonal antibody (mAb) trastuzumab, found research presented at ASCO 2013.
Lymphoseek: A New “Gold Standard” for Identifying Positive Lymph Nodes?
Lymphoseek has now demonstrated significant efficacy in diagnosis and staging of squamous cell carcinoma of the head and neck.
ASCO Debuts the CancerLINQ™ Prototype, a Knowledge-Sharing Network that May Revolutionize Cancer Care
A new database of patient information promises to change the way oncologists treat their patients in the future.
- Loading...
Loading...
Loading... 
Loading...